Literature DB >> 28088043

HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.

Kareem Ebeid1, Giang N Ho1, Aliasger K Salem2.   

Abstract

A sensitive and precise method is described for the simultaneous determination of two small molecule kinase inhibitors: MK-1775 (MK) and AZD-7762 (AZD), in acetonitrile (ACN)-aqueous solution and in mouse plasma. A Nova-Pak C18 reversed phase column (3.9mm×150mm, 4μm, 60Å) was utilized in the separation using an isocratic mobile phase of 0.1% v/v triethylamine in phosphate buffer (pH=7.4): acetonitrile (ACN) (60:40, v/v), at a flow rate of 0.8mL/min. Detection wavelength was set at 310nm for both MK and AZD, and 431nm for the internal standard sunitinib (SUN). The developed method was validated following the ICH guidelines and it was shown to be accurate, precise and linear in the range of 41ng/mL to 8333ng/mL for both drugs in the ACN-aqueous solution and from 83ng/mL to 8333ng/mL for both drugs in mouse plasma samples. For the first time, the presented data suggest the suitability of this method for the simultaneous separation and quantification of MK and AZD in both ACN aqueous solution as well as in mouse plasma samples.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AZD-7762; HPLC-UV; MK-1775; Mouse plasma; Solid phase extraction; Sunitinib

Mesh:

Substances:

Year:  2016        PMID: 28088043      PMCID: PMC5296315          DOI: 10.1016/j.jchromb.2016.12.031

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  27 in total

1.  AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.

Authors:  Sonya D Zabludoff; Chun Deng; Michael R Grondine; Adam M Sheehy; Susan Ashwell; Benjamin L Caleb; Stephen Green; Heather R Haye; Candice L Horn; James W Janetka; Dongfang Liu; Elizabeth Mouchet; Shannon Ready; Judith L Rosenthal; Christophe Queva; Gary K Schwartz; Karen J Taylor; Archie N Tse; Graeme E Walker; Anne M White
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 2.  FDA-approved small-molecule kinase inhibitors.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Trends Pharmacol Sci       Date:  2015-05-12       Impact factor: 14.819

3.  WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.

Authors:  Philip C De Witt Hamer; Shahryar E Mir; David Noske; Cornelis J F Van Noorden; Tom Würdinger
Journal:  Clin Cancer Res       Date:  2011-05-11       Impact factor: 12.531

4.  Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.

Authors:  Hee Seung Kim; Jae Weon Kim; Hong Gyun Wu; Hyun Hoon Chung; Noh Hyun Park; Yong Sang Song; Soon Beom Kang; Hyo Pyo Lee
Journal:  J Obstet Gynaecol Res       Date:  2010-06       Impact factor: 1.730

Review 5.  Advances in kinase targeting: current clinical use and clinical trials.

Authors:  Mathias Rask-Andersen; Jin Zhang; Doriano Fabbro; Helgi B Schiöth
Journal:  Trends Pharmacol Sci       Date:  2014-10-10       Impact factor: 14.819

6.  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.

Authors:  Edward Sausville; Patricia Lorusso; Michael Carducci; Judith Carter; Mary F Quinn; Lisa Malburg; Nilofer Azad; David Cosgrove; Richard Knight; Peter Barker; Sonya Zabludoff; Felix Agbo; Patricia Oakes; Adrian Senderowicz
Journal:  Cancer Chemother Pharmacol       Date:  2014-01-22       Impact factor: 3.333

7.  In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.

Authors:  James B Mitchell; Rajani Choudhuri; Kristin Fabre; Anastasia L Sowers; Deborah Citrin; Sonya D Zabludoff; John A Cook
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

8.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

Authors:  Khanh Do; Deborah Wilsker; Jiuping Ji; Jennifer Zlott; Tomoko Freshwater; Robert J Kinders; Jerry Collins; Alice P Chen; James H Doroshow; Shivaani Kummar
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

Review 9.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

Review 10.  New anti-inflammatory targets for chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.